NUVATION BIO INC (NUVB) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:NUVB - US67080N1019 - Common Stock
NUVB Key Statistics, Chart & Performance
The current stock price of NUVB is 6.99 USD. In the past month the price increased by 44.12%. In the past year, price increased by 149.64%.
NUVB Latest News, Press Relases and Analysis
NUVB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.19 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.64 | 491.06B | ||
| MRK | MERCK & CO. INC. | 11.1 | 244.18B | ||
| PFE | PFIZER INC | 7.82 | 142.37B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.05 | 94.14B | ||
| ZTS | ZOETIS INC | 19.25 | 54.09B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.47 | 22.70B | ||
| VTRS | VIATRIS INC | 4.49 | 12.20B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.18 | 11.05B | ||
| CORT | CORCEPT THERAPEUTICS INC | 87.83 | 8.14B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.46B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.04B |
Related stock screener links
About NUVB
Company Profile
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 278 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The firm's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Company Info
NUVATION BIO INC
357 Tehama Street, Floor 3
San Francisco CALIFORNIA 94103 US
CEO: David Hung
Employees: 278
Phone: 14157543517
NUVATION BIO INC / NUVB FAQ
What does NUVATION BIO INC do?
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 278 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The firm's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
What is the current price of NUVB stock?
The current stock price of NUVB is 6.99 USD. The price decreased by -0.29% in the last trading session.
Does NUVATION BIO INC pay dividends?
NUVB does not pay a dividend.
What is the ChartMill technical and fundamental rating of NUVB stock?
NUVB has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about NUVATION BIO INC (NUVB) stock?
14 analysts have analysed NUVB and the average price target is 8.89 USD. This implies a price increase of 27.16% is expected in the next year compared to the current price of 6.99.
How is the valuation of NUVATION BIO INC (NUVB) based on its PE ratio?
NUVATION BIO INC (NUVB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.64).
What is the market capitalization of NUVB stock?
NUVATION BIO INC (NUVB) has a market capitalization of 2.40B USD. This makes NUVB a Mid Cap stock.
NUVB Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NUVB. When comparing the yearly performance of all stocks, NUVB is one of the better performing stocks in the market, outperforming 98.46% of all stocks.
NUVB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NUVB. NUVB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NUVB Financial Highlights
Over the last trailing twelve months NUVB reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS decreased by -48.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.15% | ||
| ROE | -66.74% | ||
| Debt/Equity | 0.61 |
NUVB Forecast & Estimates
14 analysts have analysed NUVB and the average price target is 8.89 USD. This implies a price increase of 27.16% is expected in the next year compared to the current price of 6.99.
For the next year, analysts expect an EPS growth of -28.16% and a revenue growth 1263.17% for NUVB